http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9662345-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c882c5a87accf93b057d688a848a29
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7036
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
filingDate 2013-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2017-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cc65cc09f8597ddfbffa9ff5a0263ab
publicationDate 2017-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-9662345-B2
titleOfInvention Antibiotic composition for inhalation and irrigation
abstract An antibiotic composition for the treatment of bacterial infections, especially in the respiratory tract is provided. The antibiotic composition may include a mixture of gentamicin as active pharmaceutical ingredient (API), and a micronized poloxamer composition as excipient. Micronized poloxamer composition may be produced by mixing poloxamer 188 and poloxamer 407 in a suitable apparatus where a low-frequency acoustic field may be applied to facilitate mixing. Antibiotic composition may be obtained in powder form, or in solution, and may be administered by inhalation or irrigation. In other embodiments, a topical formulation of the antibiotic inhalation or irrigation composition may be produced. In some embodiments, other suitable poloxamers, or sugar alcohols may be employed as excipients. Due to the synergistic effect of micronized poloxamer composition, antibiotic composition may provide improved solubility and bioavailability of gentamicin, thus decreasing side effects and time of treatment.
priorityDate 2013-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4571334-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010249240-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006013871-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6161536-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011166149-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0055041-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006073198-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1922150-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006115535-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6013280-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8337815-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-RE36665-E
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1124540-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7368102-B2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID1877
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID441305
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395375
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419512635
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533858
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57134040
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID962
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID1877

Total number of triples: 42.